• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Case Control Study EvaIuation of biomarkers, genetic mutations, and epigenetic modifications in earIy diagnosis of pancreatic cancer

    2021-10-12 08:47:00BilalRahManzoorAhmadBandayGhRasoolBhatOmarShahHumiraJeelaniFizalahKawoosaTahiraYousufDilAfroze
    World Journal of Gastroenterology 2021年36期

    Bilal Rah, Manzoor Ahmad Banday, Gh Rasool Bhat, Omar J Shah, Humira Jeelani, Fizalah Kawoosa, Tahira Yousuf, Dil Afroze

    Abstract BACKGROUND Pancreatic cancer (PC) is one of the deadliest malignancies with an alarming mortality rate.Despite significant advancement in diagnostics and therapeutics,early diagnosis remains elusive causing poor prognosis, marred by mutations and epigenetic modifications in key genes which contribute to disease progression.AIM To evaluate the various biological tumor markers collectively for early diagnosis which could act as prognostic biomarkers and helps in future therapeutics of PC in Kashmir valley.METHODS A total of 50 confirmed PC cases were included in the study to evaluate the levels of carbohydrate antigen 19-9 (CA 19-9), tissue polypeptide specific antigen (TPS),carcinoembryonic antigen (CEA), vascular endothelial growth factor-A (VEGF-A),and epidermal growth factor receptor (EGFR).Mutational analysis was performed to evaluate the mutations in Kirsten rat sarcoma (KRAS), Breast cancer type 2 (BRCA-2), and deleted in pancreatic cancer-4 (DPC-4) genes.However, epigenetic modifications (methylation of CpG islands) were performed in the promoter regions of cyclin-dependent kinase inhibitor 2A (p16; CDKN2A), MutL homolog 1(hMLH1), and Ras association domain-containing protein 1(RASSF1A) genes.RESULTS We found significantly elevated levels of biological markers CA 19-9 (P ≤ 0.05),TPS (P ≤ 0.05), CEA (P ≤ 0.001), and VEGF (P ≤ 0.001).Molecular genetic analysis revealed that KRAS gene mutation is predominant in codon 12 (16 subjects, P ≤0.05), and 13 (12 subjects, P ≤ 0.05).However, we did not find a mutation in DPC-4(1203G > T) and BRCA-2 (617delT) genes.Furthermore, epigenetic modification revealed that CpG methylation in 21 (P ≤ 0.05) and 4 subjects in the promoter regions of the p16 and hMLH1 gene, respectively.CONCLUSION In conclusion, CA 19-9, TPS, CEA, and VEGF levels were significantly elevated and collectively have potential as diagnostic and prognostic markers in PC.Global data of mutation in the KRAS gene commonly in codon 12 and rare in codon 13 could augment the predisposition towards PC.Additionally, methylation of the p16 gene could also modulate transcription of genes thereby increasing the predisposition and susceptibility towards PC.

    Key Words: Pancreatic cancer; Genetic mutations; Epigenetic modifications; Biomarkers;Risk factors; Diagnostics

    INTRODUCTION

    Pancreatic cancer (PC) is one of the deadliest malignancies among several solid malignancies.It is the 15thleading cancer in the world with an overall estimated incidence of 277000 new cases which is being diagnosed every year[1].In the United States, PC is the fourth leading cause of death with a 5-year survival rate of less than 5%[2].PC is mostly found in elderly people and has been reported to be associated with several risk factors[3].The predominant risk factors include age, cigarette smoking, a high-fat diet, decreased serum levels of folate, diabetes mellitus, obesity,and chronic pancreatitis[4,5].The familial history of pancreatitis increases the probability of developing PC by around 40%[6].PC has the lowest prognosis among several solid-type tumors, mainly because almost 80% of PC patients are diagnosed when the disease is in the advanced or metastatic stage[7].Owing to the lack of specific biological biomarkers used in clinical practice for the detection of PC and its nonspecific symptomology at the initial stage of the malignancy, the early diagnosis is extremely critical to detect and analyze disease progression[8].Therefore, it is vital to identify specific biomarkers that play a key role in early diagnosis thereby improving the management and therapeutic outcome in PC.

    Tumor biomarker(s) are the substances that can be examined in body fluids (blood,urine, and other fluids), synthesized and excreted by malignant cells within the tumor tissue besides exceeding the normal level potentiating its use for cancer diagnosis and/or prognosis[9].Thus, ideally, the tumor markers should have high sensitivity and specificity, however, none of the tumor biomarkers have attained such precision[10].Recent reports suggest that commonly used biomarkers for various malignancies include carbohydrate antigen 19-9 (CA 19-9), tissue polypeptide specific antigen (TPS),carcinoembryonic antigen (CEA), vascular endothelial growth factor-A (VEGF-A), and epidermal growth factor receptor (EGFR)[11].The CA 19-9 and CEA are high molecular weight glycoproteins attached to the surface of tumor cells predominantly used in the diagnosis and prognosis of gut-associated cancers.However, marred by low sensitivity and specificity, they far from qualify for the diagnosis of other cancers[12].The group of intermediate filament proteins to which TPS belongs is mainly used to measure cytokeratin 18 and 19 and expected to reflect the tumor progression.A few studies have examined TPS expression in PC; however, the findings are contentious.Although, individually TPS expression in PC may not provide significant information about the disease progression; in concert with other tumor biological markers it is worthwhile to evaluate its role for early diagnosis, prognosis, and to predict metastatic growth of PC[13].A predominant dimeric, heparin-associated glycoprotein, VEGF-A has powerful pro-angiogenic and mitogenic activity.Elevated expression of VEGF-A enhances vascular permeability of endothelial cells and is reported to be involved in PC-associated angiogenesis[14], thus potentiates as a predictive biomarker.EGFR is a transmembrane protein that regulates cell growth and development.Mutation or elevated expression of EGFR is a key event in the pathogenesis of various malignancies such as glioblastoma, lung and oral carcinomas.There are reports of EGFR-mediated signaling associated with EGFR mutation in PC patients[15].Consequently, these reports suggest that evaluation of serum EGFR levels in PC can be a promising putative biomarker for early diagnosis and prognosis to monitor the disease status post-therapeutic interventions.Although, individually the tumor biomarkers could aid in diagnostic and prognostic evaluation to a certain level,however, collectively, they can be more beneficial to track tumor progression and could be more useful to monitor disease status.Therefore, the current study aims to evaluate the collective role of various tumor biomarkers in PC patients for their potential role in early diagnosis and application in prognosis to examine posttreatment disease status in the ethnic Kashmiri population.

    Genetic mutations play a pivotal role in tumor progression and genetic markers are critically important for the detection of malignant changes in PC[16].Approximately,97% of PC patients have alterations in genes that either follow the germline inheritance mode of transmission or occur sporadically[17].These mutations could be either oncogenic (gain of function) or diminish tumor suppressor activity (loss of function).Gain-of-function in Kirsten rat sarcoma (KRAS)a proto-oncogene that encodes guanosine triphosphatase (GTPase), is one of the prominent mediators in signal transduction pathways that are implicated in neoplastic transformation and inflammation[18].Approximately 95% of all cancers including PC are reported to harbor aKRASgene mutation which is a key event in early tumorigenesis.The majorKRASactivating gene mutations reportedly occur at codon 12 and less commonly at codon 13 and codon 61.Therefore, evaluation of genetic mutational analysis at the hotspot regions of theKRASgene could help in early diagnosis and prognosis in PC.Breast cancer type 2(BRCA-2), a tumor suppressor gene is associated with the maintenance of the genome by enhancing homologous recombination of a double-stranded break.Around 80% ofBRCA-2mutations are either frameshift or nonsense mutations that result in the formation of premature stop codons to encode non-functional BRCA-2 protein[19].Almost 7.3% of PC patients have a hereditary mutation in theBRCA-2gene which increases the risk of developing PC by approximately 20-fold[20]implicating a critical role ofBRCA-2in the early diagnosis of PC.Another vital gene,‘deleted in pancreatic cancer-4’(DPC-4)also known as SMAD family member 4,mothers against decapentaplegic homolog 4 (SMAD-4)is a tumor suppressor gene involved in the regulation of gene transcription.DPC-4 protein a downstream target of transforming growth factor-beta (TGF-β) pathway plays a critical role in the activation of TGF-β signaling thereby promotes neoplastic growth.It is reported that 30% of PC cases develop due to homozygous mutations in theDPC-4gene[21,22].Thus,mutational analysis of theDPC-4gene could be a promising factor for the early diagnosis and prognosis of PC.

    Besides genetic mutations, recent evidence suggests the epigenetic modifications such as DNA methylation plays a critical role in the pathogenesis of PC.In the recent past, reports suggest that methylation at the promoter regions of key tumor suppressor genes induces gene silencing and contributes to the development and progression of tumorigenesis[23].Various tumor suppressor genes were inactivated by epigenetic modifications.Cyclin-dependent kinase inhibitor 2A (p16; CDKN2A), a tumor suppressor gene that encodes a member of cyclin-dependent kinase inhibitor which arrests the G1-S phase of the cell cycle to prevent tumor cell progression.Loss of thep16gene is reported in 70% of cancers and around 10%-15% of the loss was due to promoter methylation[24].Thus, screening of epigenetic modifications at the promoter region of thep16gene could help in the early diagnosis of PC.MutL homolog 1 (hMLH1)a tumor suppressor gene that belongs to the mismatched repair gene family and prevents DNA damage by radiations and other associated mechanisms.hMLH1is also reported to be inactivated epigenetically by promoter methylation which leads to DNA damage.The accumulation of mismatched and damaged DNA promotes tumor cell progression[25].Ras association domain-containing protein 1(RASSF1A)is another tumor suppressor gene inactivated by promoter methylation.It is a component of RAS/PI3K/AKT and RAS/MAPK pathways.Recent reports suggest that epigenetic modifications in theRASSF1Apromoter region promote tumor progression in various cancers including kidney, breast, lung, prostate, and thyroid[26].Recent evidence suggests that 64% of pancreatic adenocarcinoma patients haveRASSF1Ahypermethylation at the promoter region, indicating that analysis of hypermethylation ofRASSF1Aat promoter region could be a promising approach for early diagnosis of PC.To summarize, these studies suggest that genetic mutations, epigenetic modulations,and elevated levels of serum biological markers play a critical role in the early diagnosis, therapeutics, and prognosis of various cancer.Therefore, keeping in consideration the documented role of tumor biomarkers, genetic mutations, and DNA methylation of tumor suppressor/protooncogenes in various malignancies including PC.The current study aimed to evaluate the serum levels of various biological tumor markers, genetic mutations, and epigenetic modifications of some key regulatory genes in PC.This would prove immensely helpful in the early diagnosis of PC, which helps in the identification of high-risk PC and may enable their development as biomarkers for future diagnostics, therapeutic interventions, and prognostics in the ethnic Kashmiri population.

    MATERIALS AND METHODS

    In this study, a total of 50 patients with pancreatic carcinoma and 50 healthy controls were included.

    Inclusion criteria

    Only the patients with histologically confirmed pancreatic carcinoma were included in this study.Written consent was taken at the very beginning from all the patients and healthy controls that were included in the study.

    Exclusion criteria

    The patients with a history of other malignancies and those who were not willing to comply with pre-requisite protocol were excluded from the study.

    Physical examination and lifestyle habits

    The study was designed and approved by the institutional review board of the Sher-i-Kashmir Institute of Medical Sciences (SKIMS), and informed consent was obtained from all participants.A comprehensive physical/clinical examination was performed in the Department of Medical Oncology, SKIMS, and the patients were evaluated for Jaundice (by examining features like yellowing of eyes and skin), pruritis (by examining features like redness, bumps, spots or blisters, dry/cracked skin and leathery/scaly skin), muscle wasting (by evaluating features like weakness or numbness in the limbs, loss of muscle coordination, tingling or weakness of the extremities, impaired balance while walking, fatigue and a general illness, facial weakness, progressive weakness, gradual memory loss and liver enlargement (were examined by features like abdominal pain, nausea/vomiting, fatigue, whitening of eyes and yellowing of the skin).

    Besides the physical examination, lifestyle activities of the PC patients were also recorded which included smoking status, salt tea consumption, spicy and non-spicy food intake, dried vegetable consumption, mutton, and beef consumption, fish consumption, oil intake, urine habits, bowel habits, and daily physical activity were also recorded.

    Laboratory findings

    The basic clinical laboratory findings were performed by using automated analyzers.The laboratory findings are liver function test (like aspartate transaminase-AST,alanine transaminase-ALT, bilirubin, and alkaline phosphatase-ALP), diabetic status(hyperglycemia) by measuring glucose levels, and anemia by measuring red blood cell(RBC) count.

    Diagnostic imaging

    For any other malignancy PC patients were initially screened by using multiphase multidetector computed tomography (CT) scan, magnetic resonance imaging (MRI),ultrasonography (USG), endoscopic ultrasound (EUS), and chest X-ray (CXR).

    Sample collection

    A total of 5 mL blood sample was collected in clot activator and Ethylenediaminetetraacetic acid (EDTA) vial from PC patients.The serum was separated from the clot activator vials using centrifugation and was stored at -80 °C for further analysis.EDTA vials contain blood was stored at -20 °C for DNA extraction.A tissue chunk (12-50 μm thick tumor tissue section) was obtained from the PC patient by endoscopy using USG-guided probes for mutational analysis and epigenetic modifications.

    Tumor biomarkers

    Tumor markers including CA19-9, TPS, CEA, VEGF-A, and EGFR were estimated in the serum obtained from blood collected from the PC patients.Measurement of CA 19-9, CEA, VEGF-A, and EGFR levels in serum were performed by using a modular E-170 analyzer.However, TPS levels in the serum were measured by using an Immulite instrument.

    Genetic mutation analysis

    Genomic DNA was extracted by the phenol-chloroform method from mononuclear cells.Hypaque density gradient centrifugation was performed to extract leucocytes from blood and tissue samples obtained from PC patients.The quantity and quality control analysis of genomic DNA was performed by carrying out UV spectrophotometer (Eppendorf Biospectrometer?, Hamburg Germany) analysis and Gel electrophoresis, respectively.However, polymerase chain reaction (PCR) was carried out with a different set of primers forKRAS,DPC-4, andBRACA-2genes under different PCR conditions.The PCR products obtained were subjected to Restriction Fragment Length Polymorphism (RFLP) using restriction enzymes BstN1 and BglI for mutational analysis ofKRAScodon 12 and 13, respectively.GGA→TGA in exon 8,codon 358 ofDPC-4gene was analyzed by using MnlI restriction enzyme.6174delT ofBRCA-2was analyzed by using allele-specific PCR technique and polyacrylamide gel electrophoresis (PAGE) was carried out to study any change in theBRCA-2gene.

    Epigenetic analysis

    The epigenetic analysis was performed by examining the methylation status of the promoter and exon regions of genes includingp16,RASSF1A,andhMLH1.The methylation status ofp16,RASSF1A,andhMLH1genes was determined by methylation-specific (MSP) PCR.Briefly, DNA extracted from tissue samples was first subjected to bisulfite conversion using EZ direct methylation kit.The bisulfiteconverted DNA was then subjected to PCR using methylated and unmethylated primers specific for the respective genes.The results were analyzed on 2% agarose gel.

    Statistical analysis

    Numerical data collected from experiments for statistical analysis were performed by using non-parametrical statistical analysis tools which are the Kruskal-Wallis test and Mann-WhitneyUtest.

    RESULTS

    The current study included 50 PC patients with a mean age of 47.82 years at the time of diagnosis for the evaluation of various tumor biological markers for the PC diagnosis.Radio-diagnostics such as USG and CT, confirmed that all 50 patients had PC.Further, histopathological analysis supported the radio-diagnostic results and revealed that out of 50 confirmed PC patients, 47 PC patients had characterized to have adenocarcinoma whereas the remaining 3 PC patients have neuroendocrine carcinoma in the pancreas as shown in Figure 1.The other demographic parameters and daily activities of all confirmed 50 PC patients are presented in Table 1.

    Owing to have relative ease in blood collection and non-invasive, it is preferred to evaluate the biological tumor markers in serum.Therefore, we also intended to evaluate the biological tumor markers which included CA 19-9, TPS, CEA, VEGF-A,and EGFR levels in the blood collected from PC patients.Our results demonstrated that the levels of serum biological tumor markers CA 19-9, CEA, VEGF-A, TPS, EGFR of PC patients were significantly raised in 33 (66%), 32 (64%), 48 (96%), 48 (96%) and 0 out of 50 PC patients, respectively (Table 2) and Figure 2.

    Although the PC progression is a heterogeneous and complex process that includes cell proliferation of intraepithelial and dysplasia to form a mass of cells, followed by an invasion of cells to neighboring tissues.Subsequently, one of the important driving factors of PC progression is genetic mutations of protooncogenes (gain-of-function)and tumor suppressor genes (loss-of-function).Among genetic mutations,KRASmutation is the key point mutation followed by deletion mutation in tumor suppressor genesBRCA-2, DPC-4,andp16in PC.To evaluate whether the PC patients in our study harbor these mutations, we sought to perform mutational analysis ofKRAShotspot codons (codon 12 and codon 13),DPC-4(1203G>T), andBRCA-2mutation(6174delT) in our PC subjects.Our mutational analysis results revealed that out of 50 PC patients, 16 and 12 PC patients hadKRASmutation at codons 12 and 13,respectively.However, we could not find mutation(s) at codons 12 and 13 of theKRASgene in the remaining 34 and 38 PC patients, respectively Figure 3.The representative agarose gel picture of the amplification product of codons 12 and 13 of theKRASgene and their RFLP pattern is shown in Figures 4 and 5.Subsequently, the mutational analysis of tumor suppressor geneDPC-4(1203G>T) andBRCA-2(6174delT) were also evaluated in all PC subjects.Interestingly, we did not find any mutations inDPC-4andBRCA-2mutation at (1203G>T) (6174delT) sites, respectively Figure 3.The representative agarose gel picture ofDPC-4(1203G>T) amplification and RFLP pattern is shown in Figure 6, respectively, and that of amplification and RFLP pattern ofBRCA-2(6174delT) is shown in Figure 7.The results obtained from the genetic mutation analysis are summarized in Table 3.

    Epigenetic alterations have been documented to play a crucial role in PC progression.Thep16, RASSF1A,andhMLH1are key tumor suppressor genes regulating mismatch repair to minimize DNA damage and are frequently inactivated by epigenetic modification in various malignancies.Therefore, we intended to investigate the epigenetic modification (methylation of CpG islands) ofp16, RASSF1A,andhMLH1genes by determining the methylation in their respective promoter regions in all PC subjects.Our epigenetic modification results demonstrated that 21 out of 50 PC subjects were found methylated in the CpG islands of the promoter region of thep16gene while the remaining 29 were unmethylated.However, the CpG islands in the promoter region ofRASSF1Awere found to be unmethylated in all 50 PC patients.Additionally, we observed that 4 out of 50 PC patients showed methylation patterns in the promoter region of thehMLH1gene, whereas the remaining 46 PC patients had thehMLH1gene unmethylated in their promoter regions.The representative agarose gel pic of MS-PCR forhMLH1andRASSF1Ais shown in Figure 8.The methylation and unmethylation status as observed in the present study forp16, hMLH1,andRASSF1Aare summarized in Table 4 and Figure 9.

    Figure 1 Distribution of samples (cases) based on subtypes of pancreatic cancer.PC: Pancreatic cancer.

    Figure 2 Analysis of tumor biological marker (carbohydrate antigen 19-9, tissue polypeptide specific antigen, carcinoembryonic antigen,vascular endothelial growth factor-A, and epidermal growth factor receptor) in the serum of pancreatic cancer patients.PC: Pancreatic cancer; CA19-9: Carbohydrate antigen 19-9; TPS: Tissue polypeptide specific antigen; CEA: Carcinoembryonic antigen; VEGF-A: Vascular endothelial growth factor-A; EGFR: Epidermal growth factor receptor.

    Figure 3 MutationaI anaIysis of KRAS (Codon 12 and 13), DPC-4, and BRCA-2 gene mutations within pancreatic cancer cases.KRAS:Kirsten rat sarcoma; DPC-4: Deleted in pancreatic cancer-4; BRCA-2: Breast cancer type 2.

    Figure 4 Representative agarose geI picture of poIymerase chain reaction ampIification (A) and restriction fragment Iength poIymorphism using BstN1 (B) for KRAS codon 12.The arrow represents the 157 bp amplicon and M denotes the DNA marker (50 bp).Lane M represents a DNA marker(50 bp).Lanes 2, 4, 7, 8, and 10 represent the mutant band (undigested) of 157 bp.Lane 1, 3, 6, and 9 represent the wild band (digested) of 128 bp.U represents the undigested band used as mutant control.

    Figure 5 Representative geI picture of poIymerase chain reaction ampIification (A) and restriction fragment Iength poIymorphism using BgII (B) for K-RAS codon 13.The arrow represents the 157 bp amplicon and M denotes the DNA marker (100 bp).Lane M represents a DNA marker (100 bp).Lanes 2, 3, 6, 7, 8, 9, 10, and 11 represent the mutant band (undigested) of 157 bp.Lanes 1, 4, 5, and 8 represent a wild band (digested) of 125 bp.

    Figure 6 Representative geI picture of poIymerase chain reaction ampIification and restriction fragment Iength poIymorphism using MnII of DPC-4.The arrow represents the 184bp amplicon and M denotes the DNA marker (100 bp).Lane M represents a DNA marker (50 bp).117 bp and 67 bp represent the wild bands (digested).U represents the mutant control band of 184 bp (undigested).

    Figure 7 Representative agarose geI picture of AS-poIymerase chain reaction ampIification (A) and geI picture representing poIyacryIamide geI eIectrophoresis (20% geI) (B) of BRCA-2.All the lanes show 151 bp amplicon which is the wild band and M denotes the DNA marker(100 bp).M is the marker lane (25 bp).Here also, the only wild band (151 bp) is observed in all the lanes.

    Figure 8 GeI picture representing MS-poIymerase chain reaction for hMLH1 (A, 100 bp) and RASSF1A (B, 25 bp).M represents DNA marker;UMC represents unmethylated control; MC represents methylated control; NM represents normal methylated; NUM represents normal unmethylated; TUM represents tumor unmethylated; TM represents tumor methylation.

    Figure 9 Methylation and unmethylation status in the promoter region of p16, RASSF1A, and hMLH1 within pancreatic cancer subjects.PC: Pancreatic cancer.

    Table 1 Characteristics and clinical presentations of cases in the present study, n (%)

    Table 2 Analysis of tumor biological marker in the serum of pancreatic cancer patients

    Table 3 Mutational analysis of KRAS (Codon 12 and 13), DPC-4, and BRCA-2 gene mutations within pancreatic cancer subjects

    Table 4 Methylation and unmethylation status in the promoter region of p16, RASSF1A, and hMLH1within pancreatic cancer subjects

    DISCUSSION

    Despite new therapeutic approaches to improve the outcome of PC patients by the introduction of molecular target approaches and combinatorial therapy, there is an unmet need to find the prospective biomarkers for early diagnosis of PC[27].Therefore, the aim of the current study was to collective evaluation of tumor biological markers, mutational status, and epigenetic modulations in PC patients of the ethnic Kashmiri population for early diagnosis.Our findings revealed the elevated levels of serum biomarkers CA 19-9, TPS, CEA, and VEGF-A, in the blood samples of PC patients, however, EGFR levels were found to be in the normal range.The mutational analysis demonstrated that theKRASgene mutation which is the major driver in PC progression was found in codons 12 (16 subjects) and 13 (12 subjects).Furthermore,DNA of CpG islands of 21 subjects was found significantly methylated in the promoter regions of thep16gene.Collectively, these results suggest that in combination with mutational analysis and epigenetic modulations (CpG methylation), the biologicaltumor markers evaluated in PC subjects could be valuable for early diagnostics and could strongly predict the PC prognostics.Additionally, these types of studies could further strengthen the validation of biological tumor markers and have a promising perspective for the predisposition and susceptibility towards PC.

    A biological tumor marker is an entity in the body that gives information about a diagnosis, prognosis, and therapeutic modalities for a particular disease.The preferred entity to be eligible as a biomarker should be available in body fluids and non-invasive[28].One of the important tumor biomarkers used in various malignancies is a high molecular weight glycoprotein CA 19-9.Biochemically, a carbohydrate antigen, CA19-9 is mainly expressed by the cells of the pancreaticobiliary system.Previous studies suggest that CA 19-9 levels were elevated in gut-associated malignancies such as gastric, bile duct, colorectal, and ovarian cancers.Owing to its relatively higher sensitivity and specificity among other biomarkers in PC patients, CA 19-9 is an important and valuable biomarker in the diagnostics of PC[29].Although reports suggest a significant progress in overall survival and reduction in CA19-9 levels in PC,however, a recent study by Hesset al[30] did not support these findings.O’Brienet al[31] reported that CA 19-9 levels were raised in PC patients and may act as a better biomarker for the early diagnosis of PC.Besides, the levels of CA 19-9 were found directly associated with tumor size, tumor burden, and stage of tumorigenesis in PC,the pre-and post-operative levels of CA 19-9 in PC patients could be used as a prognosticator.Consistent with these findings, our results revealed that out of 50 PC patients 33 had significantly elevated levels of CA 19-9 in their blood samples, which indicates that more studies with a large cohort size are needed in the future to validate CA 19-9 as a better early diagnostic biomarker in PC.

    Another valuable biomarker used in the diagnosis of various malignancies is TPS.It is essentially an antigen that binds to the epitope of soluble cytokeratin 18 fragments.The striking feature of TPS is to differentiate between PC and chronic pancreatitis and it is a better marker than CA 19-9 for differentiating PC and pancreatitis[32].Previous studies suggested that serum TPS levels have a better correlation with gastric,colorectal, and pancreatic cancer than CA 19-9, CA 195, or CEA biomarkers[33,34].Consistent with the previous studies, our results revealed that 48 out of 50 confirmed PC patients had significantly elevated levels of TPS, which suggests that elevated levels of serum TPS are better correlated with PC than CA 19-9 and could act as a better diagnostic and prognostic biomarker in PC.CEA, a glycoprotein, first identified in 1965, is present normally in the fetal pancreas, gastrointestinal tract, and liver.In the adolescent stage, it is found in lesser quantity in endodermal tissue and colon.CEA was used as a diagnostic marker of PC decades before and is now replaced by markers that have greater sensitivity for the detection of PC[35].Elevated serum levels of CEA have been documented in more than 60% of cases of PC.Consistent with previous findings, our results demonstrated that 64% of patients (32 out of 50 confirmed PC)had elevated levels of serum CEA.However, if used with other biomarkers for early diagnostics, CEA could be adding up great value to early diagnostics of PC[36].High expression of VEGF-A is associated with tumor size and progression.Overexpression of VEGF-A has been reported in head and neck, non-small cell lung, ovarian,endometrial, osteosarcoma, bladder, B cell lymphoma, ocular adnexal lymphoma,papillary renal cell carcinoma, and pancreatic cancers.VEGF-A is reported to have an 80 gene loci whose alterations are reported in hepatocarcinoma, lung, pancreatic, and endometrial cancers[36].A study conducted by Seoet al[37] demonstrated that 93% of ductal pancreatic adenocarcinomas showed high expression of VEGF-A protein.In the recent past, around 77% of VEGF-A expression was observed in PC tissues whereas only 15% of VEGF-A expression was found in the normal range[38].Consistent with these findings, our results showed that out of 50 confirmed PC subjects, 48 cases had elevated levels of VEGF-A expression, which indicates that VEGF-A plays a critical role and had a strong causal association with PC progression, thus could act as a valuable tumor biomarker in combination with other biomarkers for early diagnosis of PC.

    Besides, the currently available biomarkers for PC diagnostics, it is worthy to introduce genetic markers to develop more sophisticated tools for early detection of PC.PC is a disease that harbors somatic as well as hereditary mutations.Approximately, 5%-10% of the familial PC is caused by a mutation in a myriad of genes and surges the predisposition to PC by several-fold[24].Previous studies reported that several genes showed a strong causal association with PC progression, among these most important areKRAS, DPC-4,andBRCA-2which in turn are associated with different other genes using different interactions like physical interaction, genetic interaction, shared protein interaction,etc.as depicted in Figure 10[39].The most common mutation reported in PC isKRASmutation and is the earliest recognizable event in its pathogenesis.Studies have reported that mutations in theKRASgene are mainly limited to codon 12 and rarely on codon 13[40,41].The pathological mutation inKRASencodes constitutive Ras protein which belongs to GTP binding protein family.The constitute Ras protein facilitates the oncogenic signaling pathway which leads to inflammation, deregulated cellular growth, cell motility, and remodeling of the cytoskeletal elements.KRASgene mutations are known to be driver mutations that occur sporadically.It accounts for 30% of early neoplasms of the pancreas and nearly 100% in pancreatic adenocarcinomas.Besides PC, a mutation in theKRASgene is adequate to promote lung cancer, colon cancer, breast cancer, and other cancers as well[42,43].Recent clinical data suggest thatKRASmutations act as significant prognostic biomarker to predict therapeutic intervention for PC management.Kimet al[44]demonstrated that out of 136 PC patients, 70 PC patients harbored point mutation in codon 12 of theKRASgene, and these patients have shown dismal response to gemcitabine-based chemotherapy compared to those who had wild type allele forKRASgene[44].Another study revealed that out of 173 PC patients, 121 were found to harbor point mutations in codon 12 of theKRASgene, and among them are nonresponders to erlotinib.However, patients with wild-type alleles displayed a promising overall survival rate[45].Consistent with these studies, our mutational analysis results revealed that 16 PC patients hadKRASpoint mutation at codon 12,interestingly we observe point mutation in theKRASgene at codon 13.These findings suggest that further studies are needed to validate the high frequency of point mutation in codon 13 of theKRAS gene.BRCA-1 and BRCA-2germline mutations substantially increase the lifetime risk of breast cancer tumorigenesis.Recent reports suggest that the mutations in these genes also have a strong causal association with other cancers including PC[46].The primary role of theBRCA-2gene is the maintenance of the genome by enhancing homologous recombination of a doublestranded break.Approximately, 80% ofBRCA-2mutations are either frameshift or non-sense mutations which result in the formation of premature stop codons to encode non-functional BRCA-2 protein.BRCA-2mutations have been found in 7.3% of familial PC patients which indicates an increased risk of cancers by about 20-fold[47].DPC-4(SMAD-4)is a tumor suppressor gene intricated in the regulatory mechanisms of gene transcription.Approximately, 30% of PC cases have been reported to harbor homozygous mutations in theDPC-4gene[21].The mutatedDPC-4gene-encoded hyperactivated Smad-4 protein leads to the activation of TGF-β pathways thereby promote cell proliferation and tumor growth.Mutations in theDPC-4gene have been reported in approximately 50% of PCs and serves as a leading cause of protein inactivation[48].Inconsistent with previous studies, our mutational analysis ofBRCA-2andDPC-4genes revealed a zero frequency ofDPC-41203 G>T andBRCA-26174 deletion in PC patients.Collectively, these findings suggest that a larger sample size is needed to validate our results in the ethnic Kashmiri population.

    Figure 10 Interaction of KRAS, SMAD4 (DPC4), and BRCA2 with other genes based on various parameters.KRAS: Kirsten rat sarcoma; DPC-4:Deleted in pancreatic cancer-4; BRCA-2: Breast cancer type 2.

    Epigenetic modulations play a critical role in tumorigenesis.Change in DNA methylation of tumor suppressor genes has indispensable importance in therapeutics and could serve as biomarkers for diagnostics and prognostics in various cancers[49].p16is a tumor suppressor gene that encodes cyclin-dependent kinase inhibitors to arrest the cellular growth of malignant cells.Besides point mutations and homozygous deletions in thep16gene, recent evidence suggests that methylation of CpG islands in the promoter regions ofp16stimulates transcriptional silencing of thep16gene and contributes to PC progression.In the recent past, hypermethylation in the promoter region ofp16is significantly raised in chronic pancreatitis compared to normal;suggesting that hypermethylation in the promoter region of thep16gene might deregulate cell cycle kinetics and could promote PC progression.Further, reports demonstrated thatp16hypermethylation in chronic pancreatitis might increase the risk of PC development many-fold[48].Mooreet al[50] demonstrated the role ofp16promoter hypermethylation and associated molecular pathways involved in exocrine and endocrine development of PC.Further, studies suggest that the reduction in overall survival rate associated withp16alterations signifies the fact thatp16could act as an important diagnostic and prognostic biomarker in resected ductal PC patients[51].RASSF1Ais another tumor suppressor and an important component of RAS/PI3K/AKT and RAS/RAF/MEK/ERK pathways that have been epigenetically inactivated in various sporadic human malignancies.A higher frequency of promoter methylation status ofRASSF1Ahas been implicated in several cancers.The highest frequency ofRASSF1Apromoter hypermethylation was reported in prostate cancer(99%), followed by lung cancer (95%) and breast cancer (88%)[52].Recent reports suggest that a low frequency ofhMLH1hypermethylation was detected in PC.The loss of thehMLH1gene which encodes for Mut L protein homology 1 is common in various cancers.Further, whole-genome sequencing revealed that somatichMLH1mutations are rare in cancers with an observed frequency of < 1%[53].In the present study, we carried out epigenetic modifications (CpG methylation) of promoter regions ofp16,RASSF1A,andhMLH1genes.Our results demonstrate that significant hypermethylation (CpG islands) was reported in the promoter regions of thep16gene in PC patients.However, we observed an extremely low frequency of methylation in the promoter region of thehMLH1gene in PC patients.Interestingly, the CpG methylation in the promoter region of theRASSF1Agene was completely absent in PC patients.Additionally,in-silicoanalysis suggest that plethora of genes are associated through various interactions with the key genes (hMLH1,RASSF1A, andCDKN2A) as in Figure 11, which could play a key role in the progression of PC[39].Together, these results suggest that a cohort and comprehensive study with larger sample size is needed to document our findings in the ethnic Kashmiri population.

    Figure 11 Interaction of MLH1, RASSF1, and CDKN2A (p16) with other important genes which have a role in the progression of pancreatic cancer.

    CONCLUSION

    In conclusion, the present study strongly suggests that the elevated levels of serum CA 19-9, TPS, CEA, and VEGF-A can be used as predictive biomarkers in PC patients of the ethnic Kashmiri population and may act as prognostic biomarkers to benefit the patients who are on a different regimen of chemotherapeutic interventions.Further,mutational analysis data suggest that besides harboring point mutation in codon 12 ofKRASgene, the PC patients of the current study significantly harbored codon 13-point mutation as well, which is very rarely reported in the previous studies.This may act as a genetic risk predictor in the development of PC.Additionally, considerable hypermethylation (CpG islands) in the promoter region of thep16gene in the current study may lead to silencing of thep16gene and could also increase the predisposition towards PC.However, we could not find the association ofDPC-4G>T andBRCA-26174 deletion mutations and hypermethylation of CpG islands in the promoter region ofRASSF1AandhMLH1gene towards the risk of PC.To validate these results in the Kashmiri population the future studies need to be comprehensive and with larger sample sizes.

    ARTICLE HIGHLIGHTS

    Research background

    Pancreatic cancer (PC) is one of the deadliest malignancies with an alarming mortality rate.Despite significant advancement in diagnostics and therapeutics, early diagnosis remains elusive causing poor prognosis, marred by mutations and epigenetic modifications in key genes which contribute to disease progression.

    Research motivation

    To explore the various biological tumor markers collectively and mutational analysis of key regulatory genes for early diagnosis and prognosis of PC.

    Research objectives

    To evaluate various biological tumor markers collectively in PC and their association with genetic mutation and epigenetic modification of key regulatory genes that could act as early diagnostic and prognostic biomarkers and will help in future therapeutics of PC in Kashmir valley.

    Research methods

    The current study includes 50 confirmed PC cases to evaluate the levels of carbohydrate antigen 19-9 (CA 19-9), tissue polypeptide specific antigen (TPS),carcinoembryonic antigen (CEA), vascular endothelial growth factor-A (VEGF-A), and epidermal growth factor receptor (EGFR) by enzyme-linked immunosorbent assay(ELISA) method.Mutational analysis of key genes Kirsten rat sarcoma (KRAS), Breast cancer type 2 (BRCA-2), and deleted in pancreatic cancer-4 (DPC-4) genes was performed to evaluate the mutations at hotspot regions.Furthermore, epigenetic modifications were performed in the promoter regions of cyclin-dependent kinase inhibitor 2A (p16; CDKN2A), MutL homolog 1 (hMLH1), and Ras association domaincontaining protein 1 (RASSF1A) genes.

    Research results

    Besides significant elevation in levels of tumor markers CA 19-9 (P ≤0.05), TPS (P ≤0.05), CEA (P ≤0.001), and VEGF (P ≤0.001), our mutational analysis observed thatKRASgene mutation is predominant in codon 12 (16 subjects,P ≤0.05), and 13 (12 subjects,P ≤0.05).Additionally, epigenetic modification analysis suggests that CpG methylation was observed in 21 (P ≤0.05) and 4 subjects in the promoter regions of thep16andhMLH1gene, respectively.

    Research conclusions

    The study revealed the significant elevation of serum biological markers in PC patients and the causal association of hotspot mutations and epigenetic modification of key with PC pathogenesis thus indicates the potential of biological markers, mutational status, and epigenetic modifications of key genes collectively for predisposition,susceptibility as well as diagnostics and prognostics of PC.

    Research perspectives

    The study strongly suggests that the elevated levels of serum CA 19-9, TPS, CEA, and VEGF-A can be used as predictive biomarkers in PC subjects.Additionally, mutational analysis epigenetic modifications in the promoter region of key genes may act as prognostic biomarkers to benefit the patients who are on a different regimen of chemotherapeutic interventions.Further to validate these results, future studies need comprehensive, cohort, and explicative studies with large sample sizes.

    ACKNOWLEDGEMENTS

    The authors extend their appreciation to the State Department of Science and Technology, Jammu and Kashmir, India.

    日韩电影二区| 在线观看人妻少妇| 日日啪夜夜爽| 国产白丝娇喘喷水9色精品| a级毛片在线看网站| 亚洲综合色惰| 春色校园在线视频观看| 国产乱人偷精品视频| 亚洲国产日韩一区二区| 国产精品成人在线| 丰满迷人的少妇在线观看| 女性被躁到高潮视频| 新久久久久国产一级毛片| 女性生殖器流出的白浆| 国产熟女午夜一区二区三区 | 欧美丝袜亚洲另类| 午夜精品国产一区二区电影| 日韩成人伦理影院| 欧美日韩综合久久久久久| 久久久久久久久久久久大奶| a级毛片免费高清观看在线播放| 在现免费观看毛片| 国产乱人偷精品视频| 亚洲经典国产精华液单| 草草在线视频免费看| 久久99热这里只频精品6学生| 一边摸一边做爽爽视频免费| 蜜桃在线观看..| 久久久久久久久久久久大奶| 久久久精品94久久精品| 免费黄色在线免费观看| 欧美97在线视频| 在线天堂最新版资源| 日韩制服骚丝袜av| 一级毛片我不卡| 如何舔出高潮| 精品人妻熟女毛片av久久网站| 蜜臀久久99精品久久宅男| 中文精品一卡2卡3卡4更新| 在线观看免费高清a一片| 欧美 日韩 精品 国产| 欧美人与善性xxx| 久久99精品国语久久久| 亚洲精品av麻豆狂野| 亚洲国产欧美日韩在线播放| 成人免费观看视频高清| 国产一区二区在线观看av| 久久韩国三级中文字幕| 亚洲av在线观看美女高潮| 伦理电影大哥的女人| 汤姆久久久久久久影院中文字幕| 国产精品女同一区二区软件| 一级黄片播放器| 国产又色又爽无遮挡免| 日本与韩国留学比较| 国产精品一区二区在线不卡| 晚上一个人看的免费电影| 不卡视频在线观看欧美| 少妇人妻 视频| 精品少妇内射三级| 日本91视频免费播放| 成人免费观看视频高清| 大码成人一级视频| 51国产日韩欧美| av视频免费观看在线观看| a级毛片在线看网站| 欧美少妇被猛烈插入视频| 午夜激情av网站| 精品一品国产午夜福利视频| 一区二区三区精品91| 黄片播放在线免费| 亚洲人成网站在线播| 亚洲性久久影院| 国产精品一区二区三区四区免费观看| 午夜精品国产一区二区电影| 蜜臀久久99精品久久宅男| www.av在线官网国产| 日本-黄色视频高清免费观看| 一级,二级,三级黄色视频| 日韩伦理黄色片| 有码 亚洲区| 久久国产亚洲av麻豆专区| 能在线免费看毛片的网站| 三级国产精品片| 一级,二级,三级黄色视频| 大又大粗又爽又黄少妇毛片口| 熟女av电影| 久久久久久久久久久免费av| a级毛片在线看网站| 黑人猛操日本美女一级片| 免费高清在线观看日韩| 精品国产乱码久久久久久小说| 久久97久久精品| 熟妇人妻不卡中文字幕| 满18在线观看网站| 久久ye,这里只有精品| 久久99热6这里只有精品| 日日摸夜夜添夜夜添av毛片| 精品国产乱码久久久久久小说| 亚洲高清免费不卡视频| 日韩电影二区| 亚洲精品日韩av片在线观看| 国产免费一区二区三区四区乱码| 亚洲少妇的诱惑av| 国产永久视频网站| 久久综合国产亚洲精品| 黑人巨大精品欧美一区二区蜜桃 | 熟女电影av网| 国产一区亚洲一区在线观看| 秋霞在线观看毛片| 女人久久www免费人成看片| 搡女人真爽免费视频火全软件| 亚洲国产最新在线播放| 日韩视频在线欧美| 国产极品天堂在线| 精品少妇久久久久久888优播| 国产爽快片一区二区三区| 人体艺术视频欧美日本| 啦啦啦在线观看免费高清www| 美女国产高潮福利片在线看| 麻豆成人av视频| 欧美bdsm另类| 欧美日韩国产mv在线观看视频| 国产高清三级在线| 久久久午夜欧美精品| 青青草视频在线视频观看| 三上悠亚av全集在线观看| 亚洲人成77777在线视频| 成人国语在线视频| 少妇 在线观看| 在线精品无人区一区二区三| 久久久久久伊人网av| 女性被躁到高潮视频| 蜜桃在线观看..| 婷婷色综合大香蕉| 国产在视频线精品| 97超碰精品成人国产| 国产精品一国产av| 99久久精品国产国产毛片| 日韩一区二区视频免费看| 在线观看免费日韩欧美大片 | 成人亚洲欧美一区二区av| 色婷婷av一区二区三区视频| 亚洲欧美日韩另类电影网站| 久久鲁丝午夜福利片| 日日撸夜夜添| 在线免费观看不下载黄p国产| 国产在线视频一区二区| 大码成人一级视频| 晚上一个人看的免费电影| 国产av码专区亚洲av| 高清av免费在线| a级毛色黄片| 国产精品.久久久| 黑人高潮一二区| 水蜜桃什么品种好| 伦理电影大哥的女人| 国产成人免费观看mmmm| 曰老女人黄片| 岛国毛片在线播放| 国产亚洲欧美精品永久| 如何舔出高潮| 人妻夜夜爽99麻豆av| 97在线视频观看| 18禁动态无遮挡网站| 九九在线视频观看精品| 夫妻午夜视频| 亚洲精品乱码久久久v下载方式| 天堂中文最新版在线下载| 国产精品免费大片| 九九爱精品视频在线观看| 欧美三级亚洲精品| 午夜免费鲁丝| 免费少妇av软件| 日产精品乱码卡一卡2卡三| 卡戴珊不雅视频在线播放| 又黄又爽又刺激的免费视频.| 91午夜精品亚洲一区二区三区| 一区二区三区四区激情视频| 一级毛片aaaaaa免费看小| 日本av免费视频播放| 能在线免费看毛片的网站| 成人午夜精彩视频在线观看| 亚洲国产av新网站| 国产成人aa在线观看| 久久鲁丝午夜福利片| 国产精品人妻久久久影院| 天堂俺去俺来也www色官网| 国产免费现黄频在线看| 99九九线精品视频在线观看视频| 亚洲第一av免费看| 五月伊人婷婷丁香| a 毛片基地| 九草在线视频观看| av又黄又爽大尺度在线免费看| 观看美女的网站| 嫩草影院入口| 午夜激情av网站| 亚洲欧美色中文字幕在线| 国产av精品麻豆| 欧美日韩视频精品一区| 人人澡人人妻人| 妹子高潮喷水视频| 日日摸夜夜添夜夜添av毛片| 18在线观看网站| 成人影院久久| 一级黄片播放器| 18+在线观看网站| 国产极品天堂在线| 成人18禁高潮啪啪吃奶动态图 | 另类亚洲欧美激情| 天天操日日干夜夜撸| 精品午夜福利在线看| 日韩一区二区三区影片| 国产免费福利视频在线观看| 久久 成人 亚洲| 精品一品国产午夜福利视频| 日日撸夜夜添| 飞空精品影院首页| 2022亚洲国产成人精品| 午夜91福利影院| 国产又色又爽无遮挡免| 国产成人精品婷婷| 欧美成人午夜免费资源| 免费人妻精品一区二区三区视频| 欧美日韩国产mv在线观看视频| 国产不卡av网站在线观看| 桃花免费在线播放| 中文字幕亚洲精品专区| 在线观看免费日韩欧美大片 | 欧美精品一区二区大全| videossex国产| 免费看不卡的av| 一级毛片电影观看| 一个人免费看片子| 少妇人妻 视频| 日韩一区二区三区影片| 亚洲av欧美aⅴ国产| 亚洲高清免费不卡视频| 成年人免费黄色播放视频| 日韩中文字幕视频在线看片| 乱人伦中国视频| 国产黄频视频在线观看| 少妇 在线观看| 人体艺术视频欧美日本| 美女福利国产在线| 久久精品国产亚洲av涩爱| 777米奇影视久久| 中文字幕亚洲精品专区| 中文欧美无线码| av不卡在线播放| 国产在线免费精品| 一级二级三级毛片免费看| 国产免费又黄又爽又色| 国产成人91sexporn| 丰满饥渴人妻一区二区三| 午夜福利在线观看免费完整高清在| 视频中文字幕在线观看| 久久久欧美国产精品| 成人国语在线视频| 97在线人人人人妻| 日韩不卡一区二区三区视频在线| 麻豆乱淫一区二区| av网站免费在线观看视频| av国产久精品久网站免费入址| 亚洲欧美成人精品一区二区| 欧美少妇被猛烈插入视频| 日本91视频免费播放| 精品国产乱码久久久久久小说| 少妇熟女欧美另类| 日韩人妻高清精品专区| 国产精品久久久久成人av| 亚洲国产日韩一区二区| 日韩成人av中文字幕在线观看| 久热这里只有精品99| 极品人妻少妇av视频| 国产一级毛片在线| 成人手机av| 国产黄色视频一区二区在线观看| 午夜福利网站1000一区二区三区| 美女内射精品一级片tv| videosex国产| 亚洲,一卡二卡三卡| 国产精品人妻久久久久久| 爱豆传媒免费全集在线观看| 涩涩av久久男人的天堂| 少妇人妻久久综合中文| 少妇人妻精品综合一区二区| 纵有疾风起免费观看全集完整版| 最近手机中文字幕大全| 波野结衣二区三区在线| 视频中文字幕在线观看| 另类亚洲欧美激情| 一级毛片电影观看| 少妇的逼水好多| 久久久久视频综合| 乱码一卡2卡4卡精品| 免费观看a级毛片全部| 久久久久网色| 午夜福利在线观看免费完整高清在| 久久99热这里只频精品6学生| 国产成人午夜福利电影在线观看| 丰满乱子伦码专区| 成年女人在线观看亚洲视频| 又粗又硬又长又爽又黄的视频| av在线app专区| 99热国产这里只有精品6| 国产69精品久久久久777片| 永久免费av网站大全| 久久午夜福利片| 日本黄色日本黄色录像| 精品少妇久久久久久888优播| 亚洲精品一二三| 亚洲内射少妇av| 国产一区有黄有色的免费视频| 极品人妻少妇av视频| 99热这里只有精品一区| 又大又黄又爽视频免费| 特大巨黑吊av在线直播| av播播在线观看一区| 日韩 亚洲 欧美在线| 亚洲国产精品一区二区三区在线| 亚洲欧美清纯卡通| av.在线天堂| 午夜91福利影院| 国产精品.久久久| 精品少妇久久久久久888优播| 欧美激情 高清一区二区三区| 男女高潮啪啪啪动态图| 青春草视频在线免费观看| 亚洲综合色惰| 午夜福利视频在线观看免费| 黑人高潮一二区| 免费黄频网站在线观看国产| 各种免费的搞黄视频| 高清在线视频一区二区三区| 亚洲av.av天堂| 久久精品国产鲁丝片午夜精品| 国产国语露脸激情在线看| 晚上一个人看的免费电影| 亚洲美女黄色视频免费看| 99热6这里只有精品| 美女大奶头黄色视频| av不卡在线播放| 肉色欧美久久久久久久蜜桃| 高清欧美精品videossex| 国产有黄有色有爽视频| 99久久精品国产国产毛片| 国产熟女欧美一区二区| 亚洲欧美清纯卡通| 大话2 男鬼变身卡| 亚洲国产色片| 夜夜看夜夜爽夜夜摸| 丰满迷人的少妇在线观看| 国产欧美日韩一区二区三区在线 | 91精品伊人久久大香线蕉| 久久精品国产a三级三级三级| 高清黄色对白视频在线免费看| 综合色丁香网| 欧美97在线视频| 日韩精品有码人妻一区| 黄色视频在线播放观看不卡| 女人久久www免费人成看片| 国产精品欧美亚洲77777| 老女人水多毛片| 欧美bdsm另类| 免费看av在线观看网站| 免费观看在线日韩| 综合色丁香网| 青春草视频在线免费观看| 精品国产乱码久久久久久小说| 国产精品99久久99久久久不卡 | 免费播放大片免费观看视频在线观看| 春色校园在线视频观看| 熟女av电影| 又粗又硬又长又爽又黄的视频| 亚洲av成人精品一区久久| 97超视频在线观看视频| 久久国产精品男人的天堂亚洲 | 中文乱码字字幕精品一区二区三区| 永久网站在线| 成年人午夜在线观看视频| 欧美精品一区二区大全| 99热全是精品| 亚洲天堂av无毛| 香蕉精品网在线| 婷婷色综合大香蕉| 女的被弄到高潮叫床怎么办| 欧美日韩精品成人综合77777| 国产精品久久久久久久久免| 精品国产一区二区久久| 亚洲av在线观看美女高潮| 少妇人妻久久综合中文| 精品久久久噜噜| 爱豆传媒免费全集在线观看| h视频一区二区三区| 97在线视频观看| 97超碰精品成人国产| 国产日韩一区二区三区精品不卡 | 一级毛片电影观看| 国产精品99久久久久久久久| 91精品伊人久久大香线蕉| 大陆偷拍与自拍| 欧美 亚洲 国产 日韩一| 天堂中文最新版在线下载| 精品一区二区三区视频在线| 亚洲av国产av综合av卡| 久久99热6这里只有精品| 男人操女人黄网站| 久久精品国产亚洲av天美| 亚洲av成人精品一二三区| 黑人巨大精品欧美一区二区蜜桃 | 极品人妻少妇av视频| 老女人水多毛片| 自拍欧美九色日韩亚洲蝌蚪91| 在线观看免费视频网站a站| 欧美少妇被猛烈插入视频| 亚洲欧美成人精品一区二区| 久久97久久精品| .国产精品久久| 日韩免费高清中文字幕av| 在线看a的网站| 亚洲国产精品成人久久小说| 国模一区二区三区四区视频| 欧美激情国产日韩精品一区| 毛片一级片免费看久久久久| 制服丝袜香蕉在线| 青春草亚洲视频在线观看| 国产精品99久久久久久久久| 亚洲高清免费不卡视频| 满18在线观看网站| 青春草国产在线视频| 哪个播放器可以免费观看大片| 狠狠精品人妻久久久久久综合| 亚洲欧美成人综合另类久久久| 国产亚洲精品第一综合不卡 | 久久综合国产亚洲精品| 岛国毛片在线播放| 精品国产国语对白av| 国产精品久久久久久久电影| 精品人妻熟女av久视频| 大香蕉久久成人网| 久久精品国产亚洲av天美| 各种免费的搞黄视频| 日韩精品免费视频一区二区三区 | 久久综合国产亚洲精品| 人妻制服诱惑在线中文字幕| 一区二区三区乱码不卡18| 国产成人精品久久久久久| 欧美日韩av久久| 大香蕉久久成人网| 99久久人妻综合| 在线观看三级黄色| 亚洲欧美成人精品一区二区| 久久韩国三级中文字幕| 在线看a的网站| 国产老妇伦熟女老妇高清| 人体艺术视频欧美日本| 色视频在线一区二区三区| 大又大粗又爽又黄少妇毛片口| 免费播放大片免费观看视频在线观看| 99热这里只有是精品在线观看| 国产男女超爽视频在线观看| 高清不卡的av网站| 欧美老熟妇乱子伦牲交| 国产男女内射视频| 久久久久久久亚洲中文字幕| 黄色怎么调成土黄色| 尾随美女入室| 在线观看免费高清a一片| 午夜福利在线观看免费完整高清在| 国产黄色视频一区二区在线观看| 精品久久久久久久久亚洲| 日本91视频免费播放| 97在线视频观看| 日本黄色日本黄色录像| 免费观看的影片在线观看| 亚洲一区二区三区欧美精品| 亚洲国产成人一精品久久久| av又黄又爽大尺度在线免费看| 国产精品人妻久久久久久| 久久 成人 亚洲| 国产成人精品久久久久久| 国产乱来视频区| 一区二区av电影网| 美女中出高潮动态图| 久久人人爽av亚洲精品天堂| 99视频精品全部免费 在线| 久久久久精品性色| 欧美人与性动交α欧美精品济南到 | www.av在线官网国产| 99久久精品国产国产毛片| a级毛片在线看网站| 欧美日韩亚洲高清精品| 亚洲综合色网址| 欧美人与善性xxx| 一级毛片我不卡| 亚洲激情五月婷婷啪啪| 九九爱精品视频在线观看| 2018国产大陆天天弄谢| 成年人免费黄色播放视频| 国产精品久久久久成人av| 久久99精品国语久久久| videos熟女内射| 国产亚洲最大av| 免费大片黄手机在线观看| 日本欧美国产在线视频| 久久99蜜桃精品久久| 新久久久久国产一级毛片| 伦理电影免费视频| 人人妻人人澡人人爽人人夜夜| 黄色视频在线播放观看不卡| 最新中文字幕久久久久| 久久婷婷青草| 91精品国产国语对白视频| 男女免费视频国产| 婷婷成人精品国产| 亚州av有码| 最近2019中文字幕mv第一页| 国产欧美日韩综合在线一区二区| 青春草视频在线免费观看| xxxhd国产人妻xxx| 欧美xxⅹ黑人| 欧美成人精品欧美一级黄| 777米奇影视久久| 十八禁网站网址无遮挡| 国产精品嫩草影院av在线观看| 在线观看免费日韩欧美大片 | 国产片内射在线| 国产成人精品在线电影| 亚洲欧美日韩另类电影网站| 极品人妻少妇av视频| 热99久久久久精品小说推荐| 国产免费一区二区三区四区乱码| 久久久午夜欧美精品| 十八禁高潮呻吟视频| 亚洲精品国产色婷婷电影| 久久国产精品大桥未久av| 一级黄片播放器| 日本午夜av视频| 亚洲第一av免费看| 亚洲,一卡二卡三卡| 人成视频在线观看免费观看| 久久久久久人妻| 免费av中文字幕在线| 性高湖久久久久久久久免费观看| 九色亚洲精品在线播放| 菩萨蛮人人尽说江南好唐韦庄| 成人午夜精彩视频在线观看| 好男人视频免费观看在线| 最新的欧美精品一区二区| 久久久久久久久久久丰满| 成人影院久久| 国产精品久久久久久久电影| 婷婷色av中文字幕| 精品久久蜜臀av无| 成年人免费黄色播放视频| 丝袜脚勾引网站| 精品国产一区二区久久| 日韩一区二区视频免费看| 一级二级三级毛片免费看| 国产在线免费精品| 一级毛片电影观看| av国产久精品久网站免费入址| 91精品三级在线观看| 在线观看美女被高潮喷水网站| 久久鲁丝午夜福利片| av卡一久久| 在线天堂最新版资源| 人妻少妇偷人精品九色| 日韩av在线免费看完整版不卡| 欧美3d第一页| 搡女人真爽免费视频火全软件| 国产亚洲av片在线观看秒播厂| 久久久国产一区二区| 国产精品不卡视频一区二区| 久久精品久久精品一区二区三区| 久久精品人人爽人人爽视色| 免费观看的影片在线观看| a级毛片在线看网站| 蜜桃国产av成人99| 久久久久久伊人网av| 日韩电影二区| 美女xxoo啪啪120秒动态图| 看十八女毛片水多多多| 在现免费观看毛片| 18在线观看网站| 成年av动漫网址| 一级片'在线观看视频| 熟女av电影| 好男人视频免费观看在线| 亚洲av欧美aⅴ国产| 国产无遮挡羞羞视频在线观看| 精品久久久久久电影网| 精品视频人人做人人爽| 天堂8中文在线网| 亚洲人成77777在线视频| 日本欧美国产在线视频| 18在线观看网站| 久久久久久人妻| 亚洲国产精品一区三区| 成人毛片60女人毛片免费| 久久精品国产a三级三级三级| 欧美日韩视频高清一区二区三区二| 在线看a的网站| 日日啪夜夜爽| 天美传媒精品一区二区| 男女边摸边吃奶| 免费黄频网站在线观看国产| 亚洲欧美日韩卡通动漫| 蜜臀久久99精品久久宅男| 欧美一级a爱片免费观看看| 久久国产亚洲av麻豆专区| 大香蕉久久成人网| 久久这里有精品视频免费|